Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPotent, non-competitive NMDA receptor antagonist (IC50 = 93 nM) that has been suggested to have GluN2 (formally NR2) subunit selectivity. Inhibits inward currents evoked by NMDA in central nervous system neurons (IC50 = 350 nM) and exhibits broad anticonvulsant and antiparkinsonian activity in vivo at doses devoid of behavioral toxicity.
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
Sold under license from University of Utah
M. Wt | 3098.4 |
Formula | C127H201N35O49S3 |
Sequence |
GEXXVAKMAAXLARXNIAKGCKVNCYP (Modifications: X = Gla, Disulfide bridge between 21 - 25) |
Storage | Store at -20°C |
CAS Number | 202925-60-8 |
PubChem ID | 90488802 |
InChI Key | MJQQZSPLVNQFRB-HHXUSTKESA-N |
Smiles | [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C(O)=O)C(O)=O)C(=O)N[C@@H](CC(C(O)=O)C(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C(O)=O)C(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C(O)=O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC1=O)C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Blandl et al (2000) Structure-function relationships of the NMDA-receptor antagonist peptide, conantokin-R. FEBS Lett. 470 139 PMID: 10734223
Klein et al (2001) The amino acid residue at sequence position 5 in the conantokin peptides partially governs subunit-selective antagonism of recombinant N-MthD.-aspartate receptors. J.Biol.Chem. 276 26860 PMID: 11335724
White et al (2000) In vitro and in vivo characterization of conantokin-R, a selective NMDA receptor antagonist isolated from the venom of the fish-hunting snail Conus radiatus. J.Pharmacol.Expr.Ther. 292 425
Keywords: Conantokin-R, Conantokin-R supplier, Potent, non-competitive, NMDA, receptor, antagonists, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, venoms, GluN2, 3125, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for Conantokin-R.
There are currently no reviews for this product. Be the first to review Conantokin-R and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.